Author + information
Background: The long-term efficacy and safety of everolimus-eluting stents (EES) compared with slow-release zotarolimus-eluting stents (ZES) in patients undergoing percutaneous coronary intervention (PCI) is not known.
Methods: We performed a systematic search for randomized controlled trials comparing long-term outcomes between EES and ZES. Efficacy [target vessel revascularization (TVR) and target lesion revascularization (TLR)] and safety [major adverse cardiac events (MACE), all-cause and cardiac mortality, myocardial infarction, stent thrombosis (ST)] outcomes were evaluated at the longest reported follow-up. Random effects modeling was used to calculate pooled relative risk (RR) and 95% confidence intervals (CI).
Results: A total of 8 randomized controlled trials comprising of 11,264 patients (29,286 patient-years of follow-up) were included. There was no significant difference in TVR (RR: 0.87, CI: 0.69 – 1.11) and TLR (RR: 0.84, CI: 0.67 – 1.04) between EES and ZES respectively. Moreover, no significant difference was found in MACE (RR: 0.93, CI: 0.80 – 1.09), cardiovascular (RR: 0.91, CI: 0.69 – 1.21) and all-cause mortality (RR: 1.05, CI: 0.90 – 1.23), myocardial infarction (RR: 0.90, CI: 0.74 – 1.10), definite/probable ST (RR: 0.82, CI: 0.58 – 1.15) and definite ST (RR: 0.69, CI: 0.43 – 1.10).
Conclusions: Based on the present systematic meta-analysis in 11,264 patients, EES and slow-release ZES demonstrate overall comparable efficacy and safety in patients undergoing PCI.
Poster Contributions Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Intervention: Drug Eluting Stent & Scaffolds
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1240-133
- 2017 American College of Cardiology Foundation